Renaissance Capital logo

Tivic Health Systems Priced, Nasdaq: TIVC

Makes a non-invasive neuromodulation device for sinus and nasal inflammation.

Industry: Health Care

Latest Trade: $0.25 0.00 (0.0%)

First Day Return: +3.8%

Return from IPO: -95.1%

Industry: Health Care

Tivic Health Systems, Inc. is a commercial-phase bioelectronic medicine company focused on inflammation. Our first product, ClearUP Sinus Relief (“ClearUP”), is a patented handheld device that uses ultra-low current electrical waves to relieve symptoms of sinus and nasal inflammation. ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances: (US FDA 510(k) number K182025, US FDA De Novo number DEN200006 and EU CE Mark Certificate number CE 704687). ClearUP consistently gets high ratings from consumers across multiple sales platforms. McKinsey & Co estimates that bioelectronic medicine “represents a multibillion dollar opportunity even with modest penetration.” Bioelectronic medicine treats disease and conditions by modulating the electrical signals carried along various nerve pathways. The field grew out of the multi-billion-dollar neuromodulation industry and relied, historically, on implantable devices (e.g. pacemakers, spinal implants, deep brain stimulators). We have shown that ClearUP, a non-invasive bioelectronic therapy, can safely and comfortably deliver therapeutic benefits with a favorable safety profile.
more less
IPO Data
IPO File Date 08/03/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 3.0
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/10/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 3.0
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
ThinkEquity
Company Data
Headquarters Newark, CA, United States
Founded 2016
Employees at IPO 13
Website www.tivichealth.com

Tivic Health Systems (TIVC) Performance